You are here: Industry Insights > Samsung Biologics

News List

Samsung Biologics, STCube Ink Cancer Drug Deal contractpharma
March 09, 2020
Enter into development and manufacturing agreement for novel target anticancer drug.
Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug prnasia
March 03, 2020
Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate.
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect prnasia
February 25, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO En-CPhI.CN
November 15, 2019
Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management.
Samsung BioLogics, UCB sign third drug manufacturing deal biospectrumasia
August 01, 2019
SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy
Samsung BioLogics: A World Leader in Biopharmaceutical Manufacturing fiercepharma
May 29, 2019
Biopharmaceutical outsourcing for research and development is expected to exceed revenues of $43 billion USD by 2026, as a growing number of pharmaceutical companies turn to independent contract development and manufacturing organizations (CDMOs) to bring
Samsung Biologics signs contract with GI Innovation biospectrumasia
May 06, 2019
GI Innovation signed this second contract with Samsung BioLogics based on their satisfaction with the high quality and production services received during their first project with Samsung BioLogics in June of last year.
Samsung BioLogics wins CMO leadership awards in six categories biospectrumasia
March 23, 2019
The company has received CMO Leadership Awards including this year's awards for the sixth consecutive year since 2013
Samsung Biologics Signs CDO Deal with Eutilex firstwordpharma
March 21, 2019
Samsung Biologics signed on March 20 a contract development organization (CDO) agreement with Eutilex for developing cancer immunotherapy medicine.
More trouble for Samsung BioLogics: Prosecutors raid Korea Exchange in IPO probe fiercepharma
March 19, 2019
Samsung BioLogics has faced accounting scrutiny for nearly a year on its biosimilars joint venture with Biogen, and now the investigation has taken a new turn.

Previous page 1 2 3 4 5 6 Next page